title: ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.
abstract: BACKGROUND
  The Second International Consultation on Bladder Cancer recommendations on urothelial carcinoma (UC) of the prostate were presented at the 2011 European Association of Urology Congress in Vienna, Austria, on March 18, 2011.
  
  
  OBJECTIVE
  Our aim is to summarize the Second International Consultation on Bladder Cancer recommendations on UC of the prostate to help clinicians assess the current evidence-based management.
  
  
  METHODS
  The committee performed a thorough review of new data and updated previous recommendations. Levels of evidence and grades of recommendation were assigned based on a systematic review of the literature that included a search of online databases and review articles.
  
  
  RESULTS
  Once a non-muscle-invasive high-grade tumor or carcinoma in situ (CIS) of the bladder has been diagnosed, careful follow-up of the prostatic urethra is necessary. Noninvasive UC including CIS of the prostate should be treated with intravesical bacillus Calmette-Guérin (BCG) following endoscopic resection. A transurethral resection of the prostate may improve contact of BCG with the prostatic urethra, and it appears that response rates to BCG are increased (level of evidence: 3). Transurethral biopsy of the prostatic urethra is effective in identifying prostatic involvement but may not accurately reveal the extent of involvement, particularly with stromal invasion. Stromal invasion by UC of the prostate carries a poor prognosis. Radical cystoprostatectomy is the treatment of choice for locoregional control in patients with prostatic stromal invasion.
  
  
  CONCLUSIONS
  These recommendations contain updated information on the diagnosis and treatment of UC of the prostate. However, prospective trials are needed to further elucidate the best management of these patients.
authors.affiliation: Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Spain. jpalou@fundacio-puigvert.es
authors.forename: Juan
authors.initials: J
authors.lastname: Palou
authors.forename: David
authors.initials: D
authors.lastname: Wood
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bochner
authors.forename: Henk
authors.initials: H
authors.lastname: van der Poel
authors.forename: Hikmat A
authors.initials: HA
authors.lastname: Al-Ahmadie
authors.forename: Ofer
authors.initials: O
authors.lastname: Yossepowitch
authors.forename: Mark S
authors.initials: MS
authors.lastname: Soloway
authors.forename: Lawrence C
authors.initials: LC
authors.lastname: Jenkins
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D001706:Biopsy; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy / Q000379:methods / Q000592:standards*; D004724:Endoscopy / Q000592:standards*; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000556:secondary / Q000628:therapy*; D020728:Transurethral Resection of Prostate / Q000592:standards*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000473:pathology / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine